evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Infectious Diseases

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Relapse · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Treatment failure · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review